STARTUP
Encapsulate
Encapsulate has developed an automated tumor-on-a-chip system that grows patient-derived microtumors in their native biological state outside the human body, to screen against a variety of chemotherapeutic drugs. The microtumors are derived from a portion of the biopsy samples obtained from patients when they are initially diagnosed with cancer, grown in the biochips in a single-step process, and used to determine the most effective cancer drugs. Encapsulate’s mission is to offer personalized cancer therapy screening in the most accurate, expedited, and cost-effective manner.
Encapsulate's Story
Cancer is the second leading cause of death globally, with the mortality rates continuing to soar. Everyone has been affected by cancer in some way or the other. In the current method, chemotherapy drugs are selected and patients undergo cycles that are painful and may very well be unnecessary and avoidable. The current metric for success is a 5-year survival rate. We are determined to change the existing paradigm by improving the success rates of treatments and by improving the quality of lives of cancer patients. No loved one should endure a burden that can be prevented.